More Videos
|
CNBC'S MOST SHARED
- Apartment Vacancy Rate Hits 22-Year High
- Investing in Tech Now
- What You'll See On My NASCAR Documentary Tonight
- Warren Buffett: Economy Needs Another Dose of Viagra
- Warren Buffett Tells CNBC Consumer Sales Remain "Very, Very Soft"
- New Jobless Claims Plunge; Continuing Claims Hit Record
- Citigroup Replaces CFO, Shakes Up Top Management
- Cramer?s Outrage
- Preparing for Retirement
- Microsoft Plays a Game of Bing Pong
- July 10th in Market History
- Microsoft Plays a Game of Bing Pong
- Options Smell 'Blood' on Infosys
- Christmas in July: Consumers To Out-Scrooge Scrooge
- GM's Second Chance
- Art Cashin: Traders Weigh Obama Policy Changes
- Warren Buffett: Economy Needs Another Dose of Viagra
- Commercial Real Estate: 'Ticking Time Bomb'
- Will LeBron Dunk Tape Ever Be Released?
- Chevron Says Q2 Hit by US Refining, Weak Dollar
- Stimulus Critics Put Obama, Democrats on Defensive
- Warren Buffett: Consumer Sales Remain 'Very, Very Soft'
- Don’t Get Burned By Hot Emerging Markets
- Busch: Chinese Bank Announces Bombshell
- Lenny Dykstra: 'Bank Fraud' Led to Bankruptcy
- Christmas in July: Consumers to Out-Scrooge Scrooge
- Software Giants Rush to Cash In on Carbon-Trading
- Video Game Makers Finding Gold in Old Titles
RSS FEED
Text Size 
 |
So, yesterday I posited a theory that the weak American economy might be hurting sales growth of erectile dysfunction drugs.
The drugs are so pricey and may not be covered by insurance, so I wondered whether men might be cutting their pills in half and/or not filling their expensive prescriptions if they're having to tighten their belts.
I called attention to the fact that U.S. sales of Pfizer's [PFE
Loading...
()
] Viagra went down sequentially. Analysts say that happened even with a nine percent Viagra price increase during the quarter. And BMO Capital Markets' Bert Hazlett says in a research note to clients this morning that Viagra prescriptions did indeed drop by four percent in Q2.
Yesterday, GlaxoSmithKline [GSK
Loading...
()
] reported sequentially flat sales of Levitra. But revenue from that impotence pill is so small ($26 million), it really doesn't register.
Then, this morning, Eli Lilly [LLY
Loading...
()
] announced that second quarter sales of Cialis in the U.S. went up only $5 million from the first quarter. And here, too, the company acknowledges that it raised the price. Deutsche Bank's Barbara Ryan says total worldwide prescriptions of Cialis are up six percent so far this year. So, maybe Cialis--because it lasts a day-and-a-half versus Levitra and Viagra which last a few hours or so--is simply taking more market share. Lilly also recently launched a one-a-day version of Cialis.
In a "First on CNBC" interview on "Squawk Box" this morning new LLY CEO John Lechleiter said, "I don't think we've got a good read on whether the economy is affecting Cialis sales or not." And he mentioned something interesting that I wasn't aware of: "It's the only product overseas that is not price restricted, so it's a product most people pay for out of their pocket."
But my case may be bolstered by a Dr. Benjamin Brewer who writes "The Doctor's Office" column for The Wall Street Journal. Yesterday, in a piece about the economy's impact on healthcare he offered this anecdote: "I'm getting fewer fill (prescription) requests for E.D. drugs, like Viagra, too."
Who knew that erectile dysfunction drug prescriptions might be an economic indicator? I will resist trying to coin a term for that.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes